KEYNOTE-033: Phase 3 study of pembrolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (NSCLC)

被引：0

作者：

Zhou, C. ^{[1
]}

Caglevic, C. ^{[2
]}

Zhou, J. ^{[3
]}

Wang, B. ^{[4
]}

Wang, K. ^{[5
]}

Ge, J. ^{[6
]}

Zhou, Y. ^{[6
]}

Piperdi, B. ^{[7
]}

Ma, Z. ^{[8
]}

机构：

[1] Shanghai Pulm Hosp, Dept Oncol, Shanghai, Peoples R China

[2] FALP, Dept Oncol, Santiago, Chile

[3] Zhejiang Univ, Hosp 1, Dept Respirat, Hangzhou, Zhejiang, Peoples R China

[4] Subei Peoples Hosp, Dept Oncol, Yangzhou, Jiangsu, Peoples R China

[5] Zhejiang Univ, Hosp 2, Dept Respirat, Hangzhou, Zhejiang, Peoples R China

[6] MSD China, Oncol, Shanghai, Peoples R China

[7] Merck & Co Inc, Oncol, Kenilworth, NJ USA

[8] Henan Canc Hosp, Dept Oncol, Zhengzhou, Henan, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

466TiP

引用

页码：143 / 143

页数：1

共 50 条

[11] Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer [J].

Maruyama, Riichiroh ;

Nishiwaki, Yutaka ;

Tamura, Tomohide ;

Yamamoto, Nobuyuki ;

Tsuboi, Masahiro ;

Nakagawa, Kazuhiko ;

Shinkai, Tetsu ;

Negoro, Shunichi ;

Imamura, Fumio ;

Eguchi, Kenji ;

Takeda, Koji ;

Inoue, Akira ;

Tomii, Keisuke ;

Harada, Masao ;

Masuda, Noriyuki ;

Jiang, Haiyi ;

Itoh, Yohji ;

Ichinose, Yukito ;

Saijo, Nagahiro ;

Fukuoka, Masahiro .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (26) :4244-4252

[12] Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC) [J].

Rogado, J. ;

Pacheco-Barcia, V. ;

Fenor De la Maza, M. D. ;

Serra, J. M. ;

Toquero, P. ;

Vera, B. ;

Obispo, B. ;

Mondejar, R. ;

Ballesteros, A. ;

Donnay, O. ;

Colomer, R. ;

Sanchez-Torres, J. M. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :S1915-S1916

[13] Randomized, open-label phase III study of pembrolizumab (pembro) vs docetaxel (doce) in patients (pts) with previously treated NSCLC with PD-L1 tumour proportion score (TPS) ≥1%: KEYNOTE-033 [J].

Zhou, C. ;

Feng, J. ;

Ma, S. ;

Chen, H. ;

Ma, Z. ;

Huang, C. ;

Zhang, L. ;

He, J. ;

Wang, C. ;

Zhou, J. ;

Danchaivijtr, P. ;

Huang, H-C. ;

Vynnychenko, I. O. ;

Wang, K. ;

Orlandi, F. ;

Sriuranpong, V. ;

Li, B. ;

Ge, J. ;

Dang, T. .

ANNALS OF ONCOLOGY, 2020, 31 :S816-S816

[14] Phase II study of docetaxel and cisplatin in patients with previously untreated metastatic non-small-cell lung cancer [J].

Okamoto H. ;

Watanabe K. ;

Segawa Y. ;

Ichinose Y. ;

Yokoyama A. ;

Yoneda S. ;

Niitani H. .

International Journal of Clinical Oncology, 2000, 5 (5) :316-322

[15] Phase III Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer [J].

Nakamura, A. ;

Yoneshima, Y. ;

Morita, S. ;

Ando, M. ;

Iwasawa, S. ;

Yoshioka, H. ;

Goto, Y. ;

Takeshita, M. ;

Harada, T. ;

Hirano, K. ;

Oguri, T. ;

Kondo, M. ;

Miura, S. ;

Hosomi, Y. ;

Kato, T. ;

Kubo, T. ;

Kishimoto, J. ;

Yamamoto, N. ;

Nakanishi, Y. ;

Okamoto, I. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) :S107-S108

[16] Phase II study of docetaxel monotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC) [J].

Takigawa, N ;

Segawa, Y ;

Kishino, D ;

Fujiwara, K ;

Shinkai, T ;

Watanabe, Y ;

Tabata, M ;

Kiura, K ;

Ueoka, H ;

Tanimoto, M .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) :776S-776S

[17] Phase II pharmacodynamic trial of erlotinib in previously treated patients with advanced non-small-cell lung cancer (NSCLC):: Study results [J].

Felip, Enriqueta ;

Rojo, Frederico ;

Reck, Martin ;

Heller, Astrid ;

Klughammer, Barbara ;

Maacke, Heiko ;

Mocks, Joachim ;

Brennscheidt, Ulrich ;

Gatzemeier, Ulrich ;

Baselga, Jose .

ANNALS OF ONCOLOGY, 2006, 17 :235-235

[18] A phase IINCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer [J].

Molina, Julian R. ;

Nikcevich, Daniel ;

Hillman, Shauna ;

Geyer, Susan ;

Drevyanko, Timothy ;

Jett, James ;

Verdirame, Joseph ;

Tazelaar, Henry ;

Rowland, Kendrith ;

Wos, Edward ;

Kutteh, Leila ;

Nair, Suresh ;

Fitch, Tom ;

Flynn, Patrick ;

Stella, Philip ;

Adjei, Alex A. .

CANCER INVESTIGATION, 2006, 24 (04) :382-389

[19] EVEROLIMUS PLUS ERLOTINIB VERSUS ERLOTINIB ALONE IN PREVIOUSLY TREATED PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) [J].

Bennouna, J. ;

Besse, B. ;

Leighl, N. B. ;

Blais, N. ;

Traynor, A. M. ;

Papadimitrakopoulou, V. ;

Klimovsky, J. ;

Jappe, A. ;

Jehl, V. ;

Johnson, B. E. .

ANNALS OF ONCOLOGY, 2010, 21 :140-140

[20] A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer [J].

Yoshioka, H. ;

Katakami, N. ;

Okamoto, H. ;

Iwamoto, Y. ;

Seto, T. ;

Takahashi, T. ;

Sunaga, N. ;

Kudoh, S. ;

Chikamori, K. ;

Harada, M. ;

Tanaka, H. ;

Saito, H. ;

Saka, H. ;

Takeda, K. ;

Nogami, N. ;

Masuda, N. ;

Harada, T. ;

Kitagawa, H. ;

Horio, H. ;

Yamanaka, T. ;

Fukuoka, M. ;

Yamamoto, N. ;

Nakagawa, K. .

ANNALS OF ONCOLOGY, 2017, 28 (02) :285-291

← 1 2 3 4 5 →